Immunotherapy Approved for Stage IV

Immunotherapy Approved for Stage IV2018-04-20T16:08:41+00:00

Immunotherapy Treatments Approved for Stage IV or metastatic Non-Small Cell Lung Cancer (cancer that has spread outside of one lung)

These drugs are approved for patients with advanced non-small cell lung cancer:

First Line (as your first treatment)

  • Keytruda (pembrolizumab, a PD-1 inhibitor) – Keytruda alone can be given if you have the right biomarker. Usually, this is a test showing your cancer is PD-L1 “high” (more than half the tumor cells are positive). Less common in lung cancer, the cancer can be MSI-H (microsatellite instability high) or dMMR (mismatch repair deficient).
  • Keytruda (pembrolizumab) plus chemotherapy – Keytruda can be given with chemotherapy (Alimta(pemetrexed) and carboplatin) for advanced non-squamous lung cancer. (No test result is needed.)

Later Lines of Therapy (after another treatment)

  • Opdivo (nivolumab, a PD-1 inhibitor)
  • Keytruda (pembrolizumab, a PD-1 inhibitor) – with a positive PD-L1 biomarker test (more than 1% of cancer cells are positive)
  • Tecentriq (atezolizumab, a PD-L1 inhibitor)

Click here for answers to frequently asked questions about immunotherapy for lung cancer.

No announcement available or all announcement expired.